Aktuellt
SENASTE
Redeye ups its near-term sales estimates and adjusts its fair value range for Acarix following steps forward on the US market and the recent capital injection. The partnership with the American College of Cardiology could prove to be an important piece of the puzzle, and we see eventful times in 2023 and 2024 for Acarix.
LÄS MER
